Hormonal replacement in hypopituitarism in adults: An endocrine society clinical practice guideline

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 11, 2016, Pages 3888-3921

  Fleseriu, Maria ^a   Hashim, Ibrahim A ^b   Karavitaki, Niki ^c,d   Melmed, Shlomo ^e   Murad, M Hassan ^f   Salvatori, Roberto ^g   Samuels, Mary H ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Birmingham Women s Hospital NHS Foundation Trust   (United Kingdom)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f MAYO CLINIC   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOPRESSIN; ESTROGEN; GLUCOCORTICOID; GROWTH HORMONE; TESTOSTERONE; THYROID HORMONE;

BIOCHEMICAL ANALYSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COMORBIDITY; CONSENSUS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSECTOMY; HYPOPITUITARISM; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SURGERY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW (TOPIC); ADULT; ADVERSE EFFECTS; AGE; AGED; DRUG MONITORING; ENDOCRINOLOGY; FEMALE; HEALTH CARE ORGANIZATION; INTERNATIONAL COOPERATION; MALE; MIDDLE AGED; PERSONALIZED MEDICINE; PROCEDURES; SEXUAL DEVELOPMENT; STANDARDS;

ADULT; AGE FACTORS; AGED; CONSENSUS; DRUG MONITORING; ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPITUITARISM; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; PRECISION MEDICINE; SEX CHARACTERISTICS; SOCIETIES, SCIENTIFIC;

EID: 84994893397     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2118     Document Type: Review

References (281)

1. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
2. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666-673.
3. Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015;68:597-600.
4. Regal M, Páramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf). 2001;55:735-740.
5. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab. 1996; 81:1169-1172.
6. Bülow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf). 1997;46:75-81.
7. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336:285-288.
8. SherlockM,Reulen RC, Alonso AA, et al.ACTHdeficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009;94:4216-4223.
9. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001;357:425-431.
10. Zueger T, Kirchner P, Herren C, et al. Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab. 2012;97:E1938-E1942.
11. Ntali G, Capatina C, Fazal-Sanderson V, et al. Mortality in patients with non-functioning pituitary adenoma is increased: systematic analysis of 546 cases with long follow-up. Eur J Endocrinol. 2016; 174:137-145.
12. Hakkaart-van Roijen L, Beckers A, Stevenaert A, Rutten FF. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics. 1998;14:395-403.
13. Ehrnborg C, Hakkaart-Van Roijen L, Jonsson B, Rutten FF, Bengtsson BA, Rosén T. Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics. 2000;17:621-628.
14. Holmer H, Svensson J, Rylander L, et al. Psychosocial health and levels of employment in 851 hypopituitary Swedish patients on long-term GH therapy. Psychoneuroendocrinology. 2013;38: 842-852.
15. Swords FM. Uncertainties in endocrine substitution therapy for central hypocortisolism. Handb Clin Neurol. 2014;124:387-396.
16. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361:1881-1893.
17. Clark PM, Neylon I, Raggatt PR, Sheppard MC, Stewart PM. Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clin Endocrinol (Oxf). 1998;49:287-292.
18. Arlt W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:1059-1067.
19. Salvatori R. Adrenal insufficiency. JAMA. 2005;294:2481-2488.
20. Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 1986; 62:1173-1179.
21. Jahangiri A, Wagner J, Han SW, et al. Rate and time course of improvement in endocrine function after more than 1000 pituitary operations. Neurosurgery. 2014;61(suppl 1):163-166.
22. Webb SM, Rigla M, Wägner A, Oliver B, Bartumeus F. Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metab. 1999;84:3696-3700.
23. Crowley RK, Hamnvik OP, O'Sullivan EP, et al. Morbidity and mortality in patients with craniopharyngioma after surgery. Clin Endocrinol (Oxf). 2010;73:516-521.
24. Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:2330-2340.
25. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383:2152-2167.
26. Wattson DA, Tanguturi SK, Spiegel DY, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014;90:532-539.
27. Bleicken B, Hahner S, Ventz M, Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. Am J Med Sci. 2010;339:525-531.
28. Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol. 2015; 3:216-226.
29. Hahner S, Spinnler C, Fassnacht M, et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab. 2015; 100:407-416.
30. Burman P, Mattsson AF, Johannsson G, et al. Deaths among adult patients with hypopituitarism: hypocortisolism during acute stress, and de novo malignant brain tumors contribute to an increased mortality. J Clin Endocrinol Metab. 2013;98:1466-1475.
31. Wass JA, Arlt W. How to avoid precipitating an acute adrenal crisis. BMJ. 2012;345:e6333.
32. Beck-Peccoz P. Treatment of central hypothyroidism. Clin Endocrinol (Oxf). 2011;74:671-672.
33. Persani L. Clinical review: central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab. 2012;97:3068-3078.
34. Behan LA, Monson JP, Agha A. The interaction between growth hormone and the thyroid axis in hypopituitary patients. Clin Endocrinol (Oxf). 2011;74:281-288.
35. Ntali G, Karavitaki N. Efficacy and complications of pituitary irradiation. Endocrinol Metab Clin North Am. 2015;44:117-126.
36. Trifanescu R, Ansorge O, Wass JA, Grossman AB, Karavitaki N. Rathke's cleft cysts. Clin Endocrinol (Oxf). 2012;76:151-160.
37. Capatina C, Christodoulides C, Fernandez A, et al. Current treatment protocols can offer a normal or near-normal quality of life in the majority of patients with non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 2013;78:86-93.
38. Fernandez A, Brada M, Zabuliene L, Karavitaki N, Wass JA. Radiation-induced hypopituitarism. Endocr Relat Cancer. 2009;16: 733-772.
39. Karavitaki N, Cudlip S, Adams CB, Wass JA. Craniopharyngiomas. Endocr Rev. 2006;27:371-397.
40. Karavitaki N, Wass J. Disorders of the anterior pituitary gland. In: Warrell DD, Cox TM, Firth JD, eds. Oxford Textbook of Medicine. 5th ed. Chap 13.2. Oxford, UK: Oxford University Press; 2010:1799-1818.
41. Keating NL, O'Malley AJ, SmithMR.Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456.
42. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493-1500.
43. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833-840.
44. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86:4261-4267.
45. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599-603.
46. SmithMR,Lee H, NathanDM.Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91:1305-1308.
47. Løkkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas. 2006;53:226-233.
48. Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the Nurses' Health Study. Obstet Gynecol. 2009;113:1027-1037.
49. Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause. 2012;19:272-277.
50. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006; 13:265-279.
51. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16:15-23.
52. Lindholm J, Nielsen EH, Bjerre P, et al. Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol (Oxf). 2006; 65:51-58.
53. Juul KV, SchroederM,Rittig S, Nørgaard JP. National surveillance of central diabetes insipidus (CDI) in Denmark: results from 5 years registration of 9309 prescriptions of desmopressin to 1285 CDI patients. J Clin Endocrinol Metab. 2014;99:2181-2187.
54. Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. N Engl J Med. 2000;343: 998-1007.
55. Leroy C, Karrouz W, Douillard C, et al. Diabetes insipidus. Ann Endocrinol (Paris). 2013;74:496-507.
56. Brod M, Højbjerre L, Adalsteinsson JE, RasmussenMH.Assessing the impact of growth hormone deficiency and treatment in adults: development of a new disease-specific measure. J Clin Endocrinol Metab. 2014;99:1204-1212.
57. Sassolas G, Chazot FB, Jaquet P, et al. GH deficiency in adults: an epidemiological approach. Eur J Endocrinol. 1999;141:595-600.
58. Stochholm K, Gravholt CH, Laursen T, et al. Incidence of GH deficiency-a nationwide study. Eur J Endocrinol. 2006;155: 61-71.
59. Tanriverdi F, Schneider HJ, Aimaretti G, Masel BE, Casanueva FF, Kelestimur F. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev. 2015;36: 305-342.
60. Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN. Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab. 2015;100: 1405-1411.
61. Aguiar-Oliveira MH, Oliveira FT, Pereira RM, et al. Longevity in untreated congenital growth hormone deficiency due to a homozygous mutation in the GHRH receptor gene. J Clin Endocrinol Metab. 2010;95:714-721.
62. Toledano Y, Lubetsky A, Shimon I. Acquired prolactin deficiency in patients with disorders of the hypothalamic-pituitary axis. J Endocrinol Invest. 2007;30:268-273.
63. Tritos NA, Klibanski A. Hyperprolactinemia. JAMA. 2015;314: 1742-1743.
64. Carmichael JD. Anterior Pituitary Failure, Melmed S, editor, The Pituitary 3rd edition, Elsevier; 2011;343-381.
65. Melmed S, Jameson JL. Disorders of the anterior pituitary and hypothalamus. In: Jameson JL, ed. Harrison's Endocrinology. 2nd ed. Chap 2. New York, NY: McGraw-Hill Professional; 2010:16-49.
66. Fleseriu M, Gassner M, Yedinak C, Chicea L, Delashaw JB Jr, Loriaux DL. Normal hypothalamic-pituitary-adrenal axis by highdose cosyntropin testing in patients with abnormal response to low-dose cosyntropin stimulation: a retrospective review. Endocr Pract. 2010;16:64-70.
67. Loriaux DL, Fleseriu M. Relative adrenal insufficiency. Curr Opin Endocrinol Diabetes Obes. 2009;16:392-400.
68. Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93:4245-4253.
69. Mayenknecht J, Diederich S, Bähr V, Plöckinger U, Oelkers W. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab. 1998;83: 1558-1562.
70. Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: evaluation of the corticotropin-releasing hormone test and basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab. 2003;88:4193-4198.
71. Thaler LM, Blevins LS Jr. The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab. 1998;83:2726-2729.
72. Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:364-389.
73. Cooper MS, Stewart PM. Diagnosis and treatment of ACTH deficiency. Rev Endocr Metab Disord. 2005;6:47-54.
74. Ospina NS, Al Nofal A, Bancos I, et al. ACTH stimulation tests for the diagnosis of adrenal insufficiency: systematic review and metaanalysis. J Clin Endocrinol Metab. 2016;101:427-434.
75. Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL, Ekins S. Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction. BMC Clin Pathol. 2014;14:33.
76. Ferretti E, Persani L, Jaffrain-Rea ML, Giambona S, Tamburrano G, Beck-Peccoz P. Evaluation of the adequacy of levothyroxine replacement therapy in patients with central hypothyroidism. J Clin Endocrinol Metab. 1999;84:924-929.
77. Persani L, Ferretti E, Borgato S, Faglia G, Beck-Peccoz P. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab. 2000;85:3631-3635.
78. Alexopoulou O, Beguin C, De Nayer P, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol. 2004; 150:1-8.
79. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014; 24:1670-1751.
80. Koulouri O, AuldinMA,Agarwal R, et al. Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf). 2011;74:744-749.
81. Slawik M, Klawitter B, Meiser E, et al. Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab. 2007;92:4115-4122.
82. Martins MR, Doin FC, Komatsu WR, Barros-Neto TL, Moises VA, Abucham J. Growth hormone replacement improves thyroxine biological effects: implications for management of central hypothyroidism. J Clin Endocrinol Metab. 2007;92:4144-4153.
83. Doin FC, Rosa-Borges M, Martins MR, Moisés VA, Abucham J. Diagnosis of subclinical central hypothyroidism in patients with hypothalamic-pituitary disease by Doppler echocardiography. Eur J Endocrinol. 2012;166:631-640.
84. Hartoft-Nielsen ML, Lange M, Rasmussen AK, Scherer S, Zimmermann-Belsing T, Feldt-Rasmussen U. Thyrotropin-releasing hormone stimulation test in patients with pituitary pathology. Horm Res. 2004;61:53-57.
85. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96:1587-1609.
86. Biller BM, Samuels MH, Zagar A, et al. Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab. 2002;87:2067-2079.
87. Hamrahian AH, Yuen KC, Gordon MB, Pulaski-Liebert KJ, Bena J, Biller BM. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study. Pituitary. 2016;19:332-341.
88. Webb R, Singer M. Oxford handbook of Critical Care. Oxford; New York: Oxford University Press, 2005.
89. Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl. 1989;10:366-371.
90. Cooke RR, McIntosh JE, McIntosh RP. Circadian variation in serum free and non-SHBG-bound testosterone in normal men: measurements, and simulation using a mass action model. Clin Endocrinol (Oxf). 1993;39:163-171.
91. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab. 2009;94:907-913.
92. Spratt DI, Bigos ST, Beitins I, Cox P, Longcope C, Orav J. Both hyper-and hypogonadotropic hypogonadism occur transiently in acute illness: bio-and immunoactive gonadotropins. J Clin Endocrinol Metab. 1992;75:1562-1570.
93. Zitzmann M, Nieschlag E. Testosterone levels in healthy men and the relation to behavioural and physical characteristics: facts and constructs. Eur J Endocrinol. 2001;144:183-197.
94. Pugeat M, Lejeune H, Dechaud H, et al. Effects of drug administration on gonadotropins, sex steroid hormones and binding proteins in humans. Horm Res. 1987;28:261-273.
95. Reddy RG, Aung T, Karavitaki N, Wass JA. Opioid induced hypogonadism. BMJ. 2010;341:c4462.
96. Brambilla DJ, O'Donnell AB, Matsumoto AM, McKinlay JB. Intraindividual variation in levels of serum testosterone and other reproductive and adrenal hormones in men. Clin Endocrinol (Oxf). 2007;67:853-862.
97. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95: 2536-2559.
98. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589-598.
99. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008;93:2737-2745.
100. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53:58-68.
101. Drincic A, Arseven OK, Sosa E, Mercado M, Kopp P, Molitch ME. Men with acquired hypogonadotropic hypogonadism treated with testosterone may be fertile. Pituitary. 2003;6:5-10.
102. Silveira LF, Latronico AC. Approach to the patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2013;98: 1781-1788.
103. Ushiroyama T, Sakuma K, Ikeda A, Ueki M. Adequate reduction degree of pituitary gonadotropin levels in the clinical management of short-term hormone replacement therapy of women with menopausal symptoms. J Med. 2004;35:281-294.
104. De Bellis A, Colao A, Di Salle F, et al. A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus. J Clin Endocrinol Metab. 1999;84: 3047-3051.
105. Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA, Handelsman DJ. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab. 2005;90:5928-5936.
106. Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement of estradiol: an Endocrine Society Position Statement. J Clin Endocrinol Metab. 2013;98:1376-1387.
107. Kane J, Middle J, Cawood M. Measurement of serum testosterone in women; what should we do? Ann Clin Biochem. 2007; 44:5-15.
108. Kahric-Janicic N, Soldin SJ, Soldin OP, West T, Gu J, Jonklaas J. Tandem mass spectrometry improves the accuracy of free thyroxine measurements during pregnancy. Thyroid. 2007;17: 303-311.
109. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991;72:39-45.
110. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 1997;46:263-268.
111. Trainer PJ, McHardy KC, Harvey RD, Reid IW. Urinary free cortisol in the assessment of hydrocortisone replacement therapy. Horm Metab Res. 1993;25:117-120.
112. Grossman AB. Clinical Review#: the diagnosis and management of central hypoadrenalism. J Clin Endocrinol Metab. 2010;95:4855-4863.
113. Mah PM, Jenkins RC, Rostami-Hodjegan A, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004;61:367-375.
114. Crowley RK, Argese N, Tomlinson JW, Stewart PM. Central hypoadrenalism. J Clin Endocrinol Metab. 2014;99:4027-4036.
115. Johannsson G, Skrtic S, Lennernäs H, Quinkler M, Stewart PM. Improving outcomes in patients with adrenal insufficiency: a review of current and future treatments. Curr Med Res Opin. 2014; 30:1833-1847.
116. Hameed N, Yedinak CG, Brzana J, et al. Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary. 2013;16:452-458.
117. Yedinak C, Hameed N, Gassner M, Brzana J, McCartney S, Fleseriu M. Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors: a large single center study. Pituitary. 2015;18:701-709
118. Forss M, Batcheller G, Skrtic S, Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency-a worldwide patient survey. BMC Endocr Disord. 2012;12:8.
119. Liddle GW. Clinical pharmacology of the anti-inflammatory steroids. Clin Pharmacol Ther. 1961;2:615-635.
120. Stavreva DA, Wiench M, John S, et al. Ultradian hormone stimulation induces glucocorticoid receptor-mediated pulses of gene transcription. Nat Cell Biol. 2009;11:1093-1102.
121. Mager DE, Pyszczynski NA, Jusko WJ. Integrated QSPR-pharmacodynamic model of genomic effects of several corticosteroids. J Pharm Sci. 2003;92:881-889.
122. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf). 1997;46:255-261.
123. Benson S, Neumann P, Unger N, et al. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. Eur J Endocrinol. 2012;167:679-685.
124. Ragnarsson O, Mattsson AF, Monson JP, et al. The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients. Eur J Endocrinol. 2014;171:571-579.
125. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009;161:119-130.
126. Johannsson G, Nilsson AG, Bergthorsdottir R, et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2012;97:473-481.
127. Ekman B, Fitts D, Marelli C, Murray RD, Quinkler M, Zelissen PM. European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy. BMC Endocr Disord. 2014;14:40.
128. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:3489-3510.
129. Shimon I, Cohen O, Lubetsky A, Olchovsky D. Thyrotropin suppression by thyroid hormone replacement is correlated with thyroxine level normalization in central hypothyroidism. Thyroid. 2002;12:823-827.
130. Filipsson Nyström H, Feldt-Rasmussen U, Kourides I, et al. The metabolic consequences of thyroxine replacement in adult hypopituitary patients. Pituitary. 2012;15:495-504.
131. Klose M, Marina D, Hartoft-Nielsen ML, et al. Central hypothyroidism and its replacement have a significant influence on cardiovascular risk factors in adult hypopituitary patients. J Clin Endocrinol Metab. 2013;98:3802-3810.
132. Gordon MB, Gordon MS. Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. Endocr Pract. 1999;5:233-238.
133. Mazziotti G, Mormando M, Cristiano A, et al. Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. Eur J Endocrinol. 2014;170:893-899.
134. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81:4358-4365.
135. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82:2386-2390.
136. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab. 2000; 85:2670-2677.
137. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-2098.
138. Benito M, Vasilic B, Wehrli FW, et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res. 2005;20:1785-1791.
139. Zhang XH, Liu XS, Vasilic B, et al. In vivo microMRI-based finite element and morphological analyses of tibial trabecular bone in eugonadal and hypogonadal men before and after testosterone treatment. J Bone Miner Res. 2008;23:1426-1434.
140. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab. 1983;57:557-562.
141. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl. 1992;13:297-304.
142. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91:69-74.
143. Seftel AD, Mack RJ, Secrest AR, Smith TM. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl. 2004;25:963-972.
144. Boloña ER, UragaMV,HaddadRM,et al. Testosterone use inmen with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82: 20-28.
145. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med. 2013;10:579-588
146. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374:611-624.
147. KheraM,BhattacharyaRK,Blick G, Kushner H, Nguyen D, Miner MM. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male. 2012;15:14-21.
148. Kovac JR, Rajanahally S, Smith RP, Coward RM, Lamb DJ, Lipshultz LI. Patient satisfaction with testosterone replacement therapies: the reasons behind the choices. J Sex Med. 2014;11:553-562
149. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab. 1996;81:3469-3475.
150. Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82:407-413.
151. Swerdloff RS, Pak Y, Wang C, et al. Serum testosterone (T) level variability in T gel-treated older hypogonadal men: treatment monitoring implications. J Clin Endocrinol Metab. 2015;100: 3280-3287.
152. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;Cd002978.
153. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92: 722-727.
154. Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scand. 2004;83:892-897.
155. Tuppurainen M, Kröger H, Honkanen R, et al. Risks of perimenopausal fractures-a prospective population-based study. Acta Obstet Gynecol Scand. 1995;74:624-628.
156. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int. 2003; 14:525-530.
157. Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab. 2009;94:2277-2283.
158. Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980;2:1151-1154.
159. van der Klift M, de Laet CE, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2004;19:1172-1180.
160. MoD, Fleseriu M, Qi R, et al. Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol. 2015;3:331-338.
161. Mazziotti G, Porcelli T, Bianchi A, et al. Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur J Endocrinol. 2010;163:15-20.
162. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:3975-4011.
163. Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer. 2005;92:1293-1297.
164. Pitkin J, Rees MC, Gray S, et al. Management of premature menopause. Menopause Int. 2007;13:44-45.
165. King J, Wynne CH, Assersohn L, Jones A. Hormone replacement therapy and women with premature menopause-a cancer survivorship issue. Eur J Cancer. 2011;47:1623-1632.
166. Clemmons DR, Molitch M, Hoffman AR, et al. Growth hormone should be used only for approved indications. J Clin Endocrinol Metab. 2014;99:409-411.
167. Melmed S. Idiopathic adult growth hormone deficiency. J Clin Endocrinol Metab. 2013;98:2187-2197.
168. Johannsson G, Bjarnason R, Bramnert M, et al. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab. 1996;81: 1575-1581.
169. Beauregard C, Utz AL, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93:2063-2071.
170. Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:2048-2056.
171. Götherström G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G, Svensson J. Ten years of growth hormone (GH) replacement normalizes muscle strength in GHdeficient adults. J Clin Endocrinol Metab. 2009;94:809-816.
172. Widdowson WM, Gibney J. The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J Clin Endocrinol Metab. 2008;93:4413-4417.
173. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004;89:2192-2199.
174. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000;133:111-122.
175. DrakeWM,Rodríguez-Arnao J, Weaver JU, et al. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol (Oxf). 2001; 54:525-532.
176. Götherström G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol. 2007;156:55-64.
177. Child CJ, Conroy D, Zimmermann AG, Woodmansee WW, Erfurth EM, Robison LL. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study. Eur J Endocrinol. 2015;172: 779-790.
178. van Varsseveld NC, van Bunderen CC, Franken AA, Koppeschaar HP, van der Lely AJ, Drent ML. Tumor recurrence or regrowth in adults with nonfunctioning pituitary adenomas using GH replacement therapy. J Clin Endocrinol Metab. 2015;100:3132-3139.
179. Behan LA, Sherlock M, Moyles P, et al. Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study. Eur J Endocrinol. 2015;172:243-250.
180. Juul KV, Bichet DG, Nørgaard JP. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine. 2011;40:67-74.
181. Corona G, Giuliani C, Parenti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a metaanalysis. PLoS One. 2013;8:e80451.
182. Arima H, Oiso Y, Juul KV, Nørgaard JP. Efficacy and safety of desmopressin orally disintegrating tablet in patients with central diabetes insipidus: results of a multicenter open-label dose-titration study. Endocr J. 2013;60:1085-1094.
183. Oiso Y, Robertson GL, Nørgaard JP, Juul KV. Clinical review: treatment of neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab. 2013;98:3958-3967.
184. Janus DM, Wojcik M, Zygmunt-Górska A, Wyrobek L, Urbanik A, Starzyk JB. Adipsic diabetes insipidus in pediatric patients. Indian J Pediatr. 2014;81:1307-1314.
185. Stewart PM, Toogood AA, Tomlinson JW. Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res. 2001;56(suppl 1):1-6.
186. Gelding SV, Taylor NF, Wood PJ, et al. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxf). 1998;48:153-162.
187. Filipsson H, Johannsson G.GHreplacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol. 2009;161(suppl 1):S85-S95.
188. Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol. 2013;9:265-276
189. Giavoli C, Libé R, Corbetta S, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab. 2004;89:5397-5401.
190. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23:793-800
191. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomized, open-label, crossover study comparing the effects of oral versus transdermal estrogen therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause. 2007;14:985-994.
192. Qureshi AC, Bahri A, Breen LA, et al. The influence of the route of oestrogen administration on serum levels of cortisol-binding globulin and total cortisol. Clin Endocrinol (Oxf). 2007;66: 632-635.
193. Jørgensen JO, Møller J, Laursen T, Orskov H, Christiansen JS, Weeke J. Growth hormone administration stimulates energy ex-penditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clin Endocrinol (Oxf). 1994;41:609-614.
194. Porretti S, Giavoli C, Ronchi C, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab. 2002;87:2042-2045.
195. Agha A, Walker D, Perry L, et al. Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients. Clin Endocrinol (Oxf). 2007;66:72-77.
196. Losa M, Scavini M, Gatti E, et al. Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid. 2008;18:1249-1254.
197. Schmid C, Zwimpfer C, Brändle M, Krayenbühl PA, Zapf J, Wiesli P. Effect of thyroxine replacement on serum IGF-I, IGFBP-3 and the acid-labile subunit in patients with hypothyroidism and hypopituitarism. Clin Endocrinol (Oxf). 2006;65:706-711.
198. Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21:1081-1125.
199. Gibney J, Johannsson G, Leung KC, Ho KK. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. J Clin Endocrinol Metab. 2005;90:3897-3903.
200. Mah PM, Webster J, Jönsson P, Feldt-Rasmussen U, Koltowska-Häggström M, Ross RJ. Estrogen replacement in women of fertile years with hypopituitarism. J Clin Endocrinol Metab. 2005;90: 5964-5969.
201. Cook DM. Growth hormone and estrogen: a clinician's approach. J Pediatr Endocrinol Metab. 2004;17(suppl 4):1273-1276.
202. Linas SL, Berl T, Robertson GL, Aisenbrey GA, Schrier RW, Anderson RJ. Role of vasopressin in the impaired water excretion of glucocorticoid deficiency. Kidney Int. 1980;18:58-67.
203. Ragnar Agnarsson H, Johannsson G, Ragnarsson O. The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy. J Clin Endocrinol Metab. 2014;99:1479-1485.
204. Suliman AM, Freaney R, Smith TP, McBrinn Y, Murray B, McKenna TJ. The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2003; 59:380-387.
205. Behan LA, Kelleher G, Hannon MJ, et al. Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients. Eur J Endocrinol. 2014;170:141-150.
206. Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157:545-559.
207. McConnell EM, Bell PM, Ennis C, et al. Effects of low-dose oral hydrocortisone replacement versus short-term reproduction of physiological serum cortisol concentrations on insulin action in adult-onset hypopituitarism. Clin Endocrinol (Oxf). 2002;56: 195-201.
208. Petersons CJ, Mangelsdorf BL, Thompson CH, Burt MG. Acute effect of increasing glucocorticoid replacement dose on cardiovascular risk and insulin sensitivity in patients with adrenocorticotrophin deficiency. J Clin Endocrinol Metab. 2014;99: 2269-2276.
209. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab. 2006;91:3954-3961.
210. Behan LA, Carmody D, Rogers B, et al. Low-dose hydrocortisone replacement is associated with improved arterial stiffness index and blood pressure dynamics in severely adrenocorticotrophindeficient hypopituitary male patients. Eur J Endocrinol. 2016;174: 791-799.
211. Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary. 2008;11: 279-285.
212. Dunne FP, Elliot P, Gammage MD, et al. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism. Clin Endocrinol (Oxf). 1995;43:623-629.
213. Agha A, Liew A, Finucane F, et al. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency. Clin Endocrinol (Oxf). 2004;60:688-693.
214. Peacey SR, Wright D, Aye M, Moisey R. Glucocorticoid replacement therapy and fibrinolysis in patients with hypopituitarism. Clin Endocrinol (Oxf). 2012;77:94-98.
215. Collet TH, Bauer DC, Cappola AR, et al. Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis. J Clin Endocrinol Metab. 2014;99:3353-3362.
216. Asvold BO, Bjøro T, Platou C, Vatten LJ. Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. Clin Endocrinol (Oxf). 2012;77:911-917.
217. Tseng FY, Lin WY, Lin CC, et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. J Am Coll Cardiol. 2012;60:730-737.
218. Selmer C, Olesen JB, Hansen ML, et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab. 2014; 99:2372-2382.
219. Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172:799-809.
220. Rhee CM, Curhan GC, Alexander EK, Bhan I, Brunelli SM. Subclinical hypothyroidism and survival: the effects of heart failure and race. J Clin Endocrinol Metab. 2013;98:2326-2336.
221. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
222. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001;111:261-269.
223. Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100:2807-2831.
224. Mathioudakis N, Thapa S, Wand GS, Salvatori R. ACTH-secreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clin Endocrinol (Oxf). 2012;77:871-876.
225. Pecori Giraldi F, Andrioli M, De Marinis L, et al. Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease. Eur J Endocrinol. 2007;156:233-239.
226. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96:273-288.
227. Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89:1704-1711.
228. Karavitaki N, Dobrescu R, Byrne JV, Grossman AB, Wass JA. Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin Endocrinol (Oxf). 2013;79:217-223
229. Warfield A, Finkel DM, Schatz NJ, Savino PJ, Snyder PJ. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function. Ann Intern Med. 1984;101:783-785.
230. Mazziotti G, Marzullo P, Doga M, Aimaretti G, Giustina A. Growth hormone deficiency in treated acromegaly. Trends Endocrinol Metab. 2015;26:11-21.
231. Ku CR, Hong JW, Kim EH, Kim SH, Lee EJ. Clinical predictors of GH deficiency in surgically cured acromegalic patients. Eur J Endocrinol. 2014;171:379-387.
232. Tritos NA, Johannsson G, Korbonits M, et al. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis. J Clin Endocrinol Metab. 2014;99:2018-2029.
233. Miller KK, Wexler T, Fazeli P, et al. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab. 2010;95:567-577.
234. Giavoli C, Profka E, Verrua E, et al. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency. J Clin Endocrinol Metab. 2012;97:3983-3988.
235. Greenman Y, Tordjman K, Kisch E, Razon N, Ouaknine G, Stern N. Relative sparing of anterior pituitary function in patients with growth hormone-secreting macroadenomas: comparison with nonfunctioning macroadenomas. J Clin Endocrinol Metab. 1995; 80:1577-1583.
236. Berg C, Meinel T, Lahner H, Mann K, Petersenn S. Recovery of pituitary function in the late-postoperative phase after pituitary surgery: results of dynamic testing in patients with pituitary disease by insulin tolerance test 3 and 12 months after surgery. Eur J Endocrinol. 2010;162:853-859.
237. Tohti M, Li J, Zhou Y,HuY, Yu Z,MaC. Is peri-operative steroid replacement therapy necessary for the pituitary adenomas treated with surgery? A systematic review and meta analysis. PLoS One. 2015;10:e0119621.
238. Marko NF, Gonugunta VA, Hamrahian AH, Usmani A, Mayberg MR, Weil RJ. Use of morning serum cortisol level after transsphenoidal resection of pituitary adenoma to predict the need for longterm glucocorticoid supplementation. J Neurosurg. 2009;111: 540-544.
239. Manuylova E, Calvi LM, Vates GE, Hastings C, Shafiq I. Morning serum cortisol level after transsphenoidal surgery for pituitary adenoma predicts hypothalamic-pituitary-adrenal function despite intraoperative dexamethasone use. Endocr Pract. 2015;21:897-902.
240. Jia X, Pendharkar AV, Loftus P, et al. Utility of a glucocorticoid sparing strategy in the management of patients following transsphenoidal surgery [published online April 28, 2016)]. Endocr Pract. doi:10.4158/EP161256.OR.
241. Ladenson PW, Levin AA, Ridgway EC, Daniels GH. Complications of surgery in hypothyroid patients.AmJ Med. 1984;77:261-266.
242. Weinberg AD, Brennan MD, Gorman CA, Marsh HM, O'Fallon WM. Outcome of anesthesia and surgery in hypothyroid patients. Arch Intern Med. 1983;143:893-897.
243. Devin JK. Hypopituitarism and central diabetes insipidus: perioperative diagnosis and management. Neurosurg Clin N Am. 2012; 23:679-689.
244. Zada G, Sivakumar W, Fishback D, Singer PA, Weiss MH. Significance of postoperative fluid diuresis in patients undergoing transsphenoidal surgery for growth hormone-secreting pituitary adenomas. J Neurosurg. 2010;112:744-749.
245. Rajaratnam S, Seshadri MS, Chandy MJ, Rajshekhar V. Hydrocortisone dose and postoperative diabetes insipidus in patients undergoing transsphenoidal pituitary surgery: a prospective randomized controlled study. Br J Neurosurg. 2003;17:437-442.
246. Raff H. Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol. 1987;252:R635-R644.
247. Raff H, Skelton MM, Cowley AW Jr. Cortisol inhibition of vasopressin and ACTH responses to arterial hypotension in conscious dogs. Am J Physiol. 1990;258:R64-R69.
248. Baylis C, Handa RK, Sorkin M. Glucocorticoids and control of glomerular filtration rate. Semin Nephrol. 1990;10:320-329.
249. Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB, Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol (Oxf). 1999;50: 561-567.
250. Salem M, Tainsh RE Jr, Bromberg J, Loriaux DL, Chernow B. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg. 1994;219:416-425.
251. Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery. 1997;121:123-129.
252. Lindsay JR, Nieman LK. The hypothalamic-pituitary-adrenal axis in pregnancy: challenges in disease detection and treatment. Endocr Rev. 2005;26:775-799.
253. Kamoun M, Mnif MF, Charfi N, et al. Adrenal diseases during pregnancy: pathophysiology, diagnosis and management strategies. Am J Med Sci. 2014;347:64-73.
254. Suri D, Moran J, Hibbard JU, Kasza K, Weiss RE. Assessment of adrenal reserve in pregnancy: defining the normal response to the adrenocorticotropin stimulation test. J Clin Endocrinol Metab. 2006;91:3866-3872.
255. Durr JA, Lindheimer MD. Diagnosis and management of diabetes insipidus during pregnancy. Endocr Pract. 1996;2:353-361.
256. Ball SG. Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin. Ann Clin Biochem. 2007; 44:417-431.
257. Källén BA, Carlsson SS, Bengtsson BK. Diabetes insipidus and use of desmopressin (Minirin) during pregnancy. Eur J Endocrinol. 1995;132:144-146.
258. Vila G, Akerblad AC, Mattsson AF, et al. Pregnancy outcomes in women with growth hormone deficiency. Fertil Steril. 2015;104: 1210-1217.e1.
259. Famini P, Melmed S. Pituitary apoplexy. In: Loriaux L, ed Endocrine Emergencies: Recognition and Treatment. New York, NY: Humana Press; 2014:175-211.
260. Arafah BM, Harrington JF, Madhoun ZT, Selman WR. Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab. 1990;71:323-328.
261. Veldhuis JD,HammondJM. Endocrine function after spontaneous infarction of the human pituitary: report, review, and reappraisal. Endocr Rev. 1980;1:100-107.
262. Capatina C, Inder W, Karavitaki N, Wass JA. Management of endocrine disease: pituitary tumour apoplexy. Eur J Endocrinol. 2015;172:R179-R190.
263. Cardoso ER, Peterson EW. Pituitary apoplexy: a review. Neurosurgery. 1984;14:363-373.
264. Laws ER. Pituitary tumor apoplexy: a review. J Intensive Care Med. 2008;23:146-147.
265. Randeva HS, Schoebel J, Byrne J, Esiri M, Adams CB, Wass JA. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf). 1999;51:181-188.
266. Ayuk J, McGregor EJ, Mitchell RD, Gittoes NJ. Acute management of pituitary apoplexy-surgery or conservative management? Clin Endocrinol (Oxf). 2004;61:747-752.
267. Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf). 2011;74:9-20.
268. Verrees M, Arafah BM, Selman WR. Pituitary tumor apoplexy: characteristics, treatment, and outcomes. Neurosurg Focus. 2004; 16:E6.
269. Maccagnan P, Macedo CL, Kayath MJ, Nogueira RG, Abucham J. Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab. 1995;80:2190-2197.
270. Sibal L, Ball SG, Connolly V, et al. Pituitary apoplexy: a review of clinical presentation, management and outcome in 45 cases. Pituitary. 2004;7:157-163.
271. Paragliola RM, Prete A, Kaplan PW, Corsello SM, Salvatori R. Treatment of hypopituitarism in patients receiving antiepileptic drugs. Lancet Diabetes Endocrinol. 2015;3:132-140.
272. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther. 1996;277:105-112.
273. Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther. 1987;42:424-432.
274. Burstein S, Klaiber EL. Phenobarbital-induced increase in 6-hydroxycortisol -xcretion: clue to its significance in human urine. J Clin Endocrinol Metab. 1965;25:293-296.
275. Högler W, Wudy SA, Luef G, Hartmann MF, Rauchenzauner M. Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction. Arch Dis Child. 2010;95:1065.
276. Werk EE Jr, Macgee J, Sholiton LJ. Effect of diphenylhydantoin on cortisol metabolism in man. J Clin Invest. 1964;43:1824-1835.
277. Carl JS, Weaver SP, Tweed E, Edgerton L. Effect of antiepileptic drugs on oral contraceptives. Am Fam Physician. 2008;78:634-635.
278. Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or carbamazepine.A paradox resolved. JAMA. 1996;275:1495-1498.
279. Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47:1447-1451.
280. Erel CT, Brincat M, Gambacciani M, et al. EMAS position statement: managing the menopause in women with epilepsy. Maturitas. 2010;66:327-328.
281. Raw variability data was obtained with permission from published BioRad Unity quality control data (Bio-Rad Laboratories I 9500 Jeronimo Road, Irvine,CA92 618). Information on sample stability was summarized from respective manufacturers' published information.